Antibacterial treatment of invasive mechanical ventilation-associated pneumonia

Drugs and Aging

Volumn 18, Issue 3, 2001, Pages 189-200

  Barcenilla, F ^a   Gasco E ^a   Rello, J ^b   Alvarez Rocha, L ^c  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; LEVOFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL FLORA; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORBIDITY; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS;

EID: 0035068279     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118030-00004     Document Type: Review

References (62)

1. Infection control and presentation strategies in the ICU
2. Epidemiología de la neumonía nosocomial adquirida en UCI
3. Surveillance of ICU-acquired infection: A Spanish nationwide study
4. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study
5. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1990-May 1999, issued June 1999
6. Effect of ventilator-associated pneumonia on mortality and morbidity
7. Facial mask noninvasive mechanical ventilation reduces the incidence of nosocomial pneumonia: A prospective epidemiological survey from a single ICU
8. Nosocomial pneumonia and mortality among patients in intensive care units
9. Microbial etiology of acute pneumonia in hospitalized patients
10. ICU infections in Spain: Time trends of etiology and resistances from 1994 to 1998
11. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1997, issued May 1997
12. Microbial causes of ventilator-associated pneumonia
13. Incidence, etiology and outcome of nosocomial pneumonia in mechanically ventilated patients
14. The role of Candida spp isolated from bronchoscopic samples in nonneutropenic patients
15. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
16. The value of routine microbial investigation in ventilator-associated pneumonia
17. Nosocomial respiratory tract infections in multiple trauma patients: Influence of level of consciousness with implications for therapy
18. Pulmonary infiltrates in the surgical ICU. Prospective assessment of predictors of etiology and mortality
19. Pneumonia in acute respiratory distress syndrome: A prospective evaluation of bilateral bronchoscopic sampling
20. Nosocomial pneumonia in patients with acute respiratory distress syndrome
21. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy and preventive strategies. A consensus statement
22. Ventilator-associated bacterial pneumonia: Challenges in diagnosis, treatment, and prevention
23. Etiology of the pneumonia acquired in intensive care units: Predisposing factors
24. Bactéries isolées de prélèvements bronchopulmonaires protégés: Variation en fonction de la durée de séjour préalable en réanimation
25. Utility of Grams stain and efficacy of quantitative cultures for posttraumatic pneumonia
26. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria
27. Variations in etiology of ventilator-associated pneumonia across four treatment sites
28. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia
29. Diagnóstico y tratamiento de la neumonía nosocomial
30. Ventilator-associated pneumonia by Staphylococcus aureus: Comparison of methicillin-resistant and methicillin-sensitive episodes
31. Tratamiento de la neumonía-nosocomial
32. Nosocomial pneumonia: A multivariate analysis of risk and prognosis
33. Incidence, risk and prognosis of nosocomial pneumonia in mechanically patients
34. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients
35. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
36. The influence of min:-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia
37. Empirical antimicrobial therapy of mechanically ventilated patients with nosocomial pneumonia
38. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients
39. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
40. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study
41. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients
42. Prospective observational study of Klebsiella bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy
43. Monotherapy versus betalactam-aminoglycoside combination treatment for Gram-negative bacteremia: A prospective observational study
44. Nosocomial pneumonia: Pathogenesis and recent advances in diagnosis and therapy
45. Nosocomial pneumonia guidelines. An international perspective
46. Aspiration pneumonia
47. Amoxicillin/clavulanate vs clindamycin in the treatment of anaerobic lung infections
48. Comparative study with enoxacin and netelmicin in a pharmacodynamic model to determine the importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
49. Pathogens resistant to antimicrobial agents: Epidemiology, molecular mechanisms and clinical management
50. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin
51. Editorial response: Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides
52. Single or multiple daily doses of aminoglycosides: A meta-analysis
53. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
54. Continuous infusion versus intermitent administration of ceftazidime in critically ill patients with suspected Gram-negative infections
55. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
56. Aerosolized antibiotics in mechanically ventilated patients: Delivery and response
57. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: Pharmacokinetics and absolute bioavailability
58. Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia
59. Invasive diagnostic testing is not needed routinely to manage suspected ventilator-associated pneumonia
60. Impact of invasive and noninvasive quantitative cultures sampling on outcome of ventilator-associated pneumonia
61. Mortality of nosocomial pneumonia in ventilated patients: Influence of diagnostic tools
62. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients